PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDextroamphetamine
Dextroamphetamine
Adderall, Amphetamine / Amphetamine / Dextroamphetamine / Dextroamphetamine, Biphetamine, Delcobese, Dexedrine Spansule, Dextroamphetamine, Mydayis, Xelstrym (dextroamphetamine) is a small molecule pharmaceutical. Dextroamphetamine was first approved as Delcobese on 1982-01-01. It is used to treat attention deficit disorder with hyperactivity and narcolepsy in the USA. The pharmaceutical is active against sodium-dependent dopamine transporter and sodium-dependent noradrenaline transporter. In addition, it is known to target trace amine-associated receptor 1.
Download report
Favorite
Top Prescription Drugs
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
mental disordersD001523
Trade Name
FDA
EMA
Dexedrine spansule, Dextroamphetamine, Xelstrym (discontinued: Dexampex, Dexedrine, Dextroamphetamine, Dextrostat, Ferndex)
Combinations
Adderall, Dextroamp saccharate, amp aspartate, dextroamp amp, Dyanavel, Mydayis (discontinued: Adderall, Biphetamine, Delcobese, Dextroamp saccharate, amp aspartate, dextroamp amp, Dextroamp saccharate,amp aspartate,dextroamp amp)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amphetamine aspartate
+
Amphetamine sulfate
+
Dextroamphetamine saccharate
+
Dextroamphetamine sulfate
Tradename
Company
Number
Date
Products
ADDERALL XR 10TakedaN-021303 RX2001-10-11
1 products, RLD
ADDERALL XR 20TakedaN-021303 RX2001-10-11
1 products, RLD
ADDERALL XR 30TakedaN-021303 RX2001-10-11
1 products, RLD, RS
ADDERALL XR 25TakedaN-021303 RX2002-05-22
1 products, RLD
ADDERALL XR 5TakedaN-021303 RX2002-05-22
1 products, RLD
ADDERALL XR 15TakedaN-021303 RX2002-05-22
1 products, RLD
MYDAYISTakedaN-022063 RX2017-06-20
4 products, RLD, RS
Show 7 discontinued
Dextroamphetamine sulfate
Tradename
Company
Number
Date
Products
DEXEDRINE SPANSULEImpax LaboratoriesN-017078 RX1982-01-01
3 products, RLD, RS
Amphetamine
+
Amphetamine aspartate
+
Dextroamphetamine sulfate
Tradename
Company
Number
Date
Products
DYANAVEL XRTris PharmaN-208147 RX2015-10-19
1 products, RLD, RS
DYANAVEL XR 5Tris PharmaN-210526 RX2021-11-04
1 products, RLD
DYANAVEL XR 10Tris PharmaN-210526 RX2021-11-04
1 products, RLD
DYANAVEL XR 15Tris PharmaN-210526 RX2021-11-04
1 products, RLD
DYANAVEL XR 20Tris PharmaN-210526 RX2021-11-04
1 products, RLD, RS
Dextroamphetamine
Tradename
Company
Number
Date
Products
XELSTRYMNoven PharmaceuticalsN-215401 RX2022-03-22
4 products, RLD, RS
Amphetamine resin complex
+
Dextroamphetamine resin complex
Tradename
Company
Number
Date
Products
BIPHETAMINE 20UCBN-010093 DISCN1982-01-01
1 products
BIPHETAMINE 12.5UCBN-010093 DISCN1982-01-01
1 products
BIPHETAMINE 7.5UCBN-010093 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
adderallNew Drug Application2025-03-13
adderall xrNew Drug Application2010-03-29
dexedrineNew Drug Application2023-10-23
dextroamphetamineANDA2025-03-26
dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfateANDA2023-10-20
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfateANDA2025-04-01
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfateANDA2024-02-05
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-releaseANDA2024-02-01
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfateANDA2024-12-27
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-releaseANDA2024-01-12
Show 13 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
narcolepsyEFO_0000614D009290G47.4
attention deficit disorder with hyperactivityEFO_0003888D001289F90
Agency Specific
FDA
EMA
Expiration
Code
DEXTROAMPHETAMINE, XELSTRYM, NOVEN PHARMS INC
2025-03-22NP
AMPHETAMINE ASPARTATE / AMPHETAMINE SULFATE / DEXTROAMPHETAMINE SACCHARATE / DEXTROAMPHETAMINE SULFATE, MYDAYIS, TAKEDA PHARMS USA
2023-03-13PED
Patent Expiration
Patent
Expires
Flag
FDA Information
Dextroamphetamine, Xelstrym, Noven Pharms Inc
115595012042-01-06DP
94569932033-10-24DPU-3340
94747222033-10-24DP
85919412025-10-07DP
86328022025-10-07DP
90343702025-10-07DP
Amphetamine Aspartate / Amphetamine Sulfate / Dextroamphetamine Saccharate / Dextroamphetamine Sulfate, Mydayis, Takeda Pharms Usa
88461002029-08-24DP
91738572026-05-12U-2025
69137682023-05-24DPU-2025
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06B: Psychostimulants, agents used for adhd and nootropics
— N06BA: Centrally acting sympathomimetics
— N06BA02: Dexamfetamine
HCPCS
Code
Description
S0160
Dextroamphetamine sulfate, 5 mg
Clinical
Clinical Trials
107 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Attention deficit disorder with hyperactivityD001289EFO_0003888F90510491136
HyperkinesisD006948——4536824
Substance-related disordersD019966EFO_0003890F1314—149
DepressionD003863—F33.9—2—114
Depressive disorderD003866EFO_1002014F32.A—2—114
Bipolar disorderD001714EFO_0000289F30.911—1—3
StrokeD020521EFO_0000712I63.9—2—1—3
Autism spectrum disorderD000067877—F84.0—1—1—2
Conduct disorderD019955EFO_0004216F91———2—2
Major depressive disorderD003865EFO_0003761F22———112
Show 14 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GliomaD005910EFO_0000520———1——1
AstheniaD001247EFO_0007625R53.1——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cocaine-related disordersD019970—F1478——419
Healthy volunteers/patients———61——310
Opioid-related disordersD009293EFO_0005611F11—2——24
SchizophreniaD012559EFO_0000692F20—2——24
NarcolepsyD009290EFO_0000614G47.421———3
Amphetamine-related disordersD019969EFO_0004701F1513———3
Psychotic disordersD011618—F20.81—1——12
AnhedoniaD059445—R45.8411———2
Disorders of excessive somnolenceD006970—G47.1—1——12
Addictive behaviorD016739EFO_0004347——1——12
Show 9 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug misuseD000076064——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Tobacco use disorderD014029—F17————33
AlcoholismD000437EFO_0003829F10.1————22
HivD006678—O98.7————11
HemorrhageD006470MP_0001914R58————11
Heart failureD006333EFO_0003144I50————11
HypertensionD006973EFO_0000537I10————11
Covid-19D000086382—U07.1————11
InfectionsD007239EFO_0000544—————11
Coronavirus infectionsD018352EFO_0007224B34.2————11
MenorrhagiaD008595EFO_0003945N92.0————11
Show 34 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDextroamphetamine
INNdexamfetamine
Description
(S)-amphetamine is a 1-phenylpropan-2-amine that has S configuration. It has a role as a neurotoxin, an adrenergic uptake inhibitor, a dopaminergic agent, a sympathomimetic agent, a dopamine uptake inhibitor and an adrenergic agent. It is an enantiomer of a (R)-amphetamine.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@H](N)Cc1ccccc1
Identifiers
PDB—
CAS-ID51-64-9
RxCUI—
ChEMBL IDCHEMBL612
ChEBI ID4469
PubChem CID5826
DrugBankDB01576
UNII IDTZ47U051FI (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Mydayis – Shire
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Adderall – Shire
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Adderall – Takeda
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Dextroamphetamine
+
Amphetamine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Dextroamphetamine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 6,061 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adderall, Adderall xr, Dexedrine, Dextroamphetamine, Dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate tablets,cii, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate, Dextroamphetamine sulfate, Mixed salts of a single entity amphetamine product, Mixed salts of a single-entity amphetamine product, Mydayis, Procentra, Xelstrym, Zenzedi
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
35,867 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use